Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 19;1(3):otz026. doi: 10.1093/crocol/otz026

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FIGURE 3. — (A) We evaluated pre-infliximab whole blood neutrophil CD64 surface expression (nCD64) between biochemical remitters (fecal calprotectin < 250 µg/g) and nonremitters at the end of induction with the Mann–Whitney test. (B) Study participants were classified as high risk (OSM^high/nCD64^high) based on their pretreatment plasma OSM and nCD64 concentrations. High-risk patients had lower rates of biochemical remission at the end of induction (W12) and at W52 compared with the low-risk group. Rates of remission were compared by the Fisher exact test.